Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma

Trial Profile

A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2019

At a glance

  • Drugs Tisagenlecleucel (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms ELARA
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 26 Nov 2018 Planned End Date changed from 17 Aug 2022 to 24 Aug 2022.
    • 26 Nov 2018 Planned primary completion date changed from 12 Feb 2021 to 19 Feb 2021.
    • 05 Sep 2018 Planned End Date changed from 7 Apr 2022 to 17 Aug 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top